# ORB-011 In Patients With Advanced Solid Tumors

> **NCT05947474** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Orionis Biosciences Inc** · enrollment: 55 (actual)

## Conditions studied

- Advanced Solid Cancer

## Interventions

- **DRUG:** ORB-011

## Key facts

- **NCT ID:** NCT05947474
- **Lead sponsor:** Orionis Biosciences Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-08-21
- **Primary completion:** 2026-03
- **Final completion:** 2026-03
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05947474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05947474, "ORB-011 In Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05947474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*